Targeting unmet needs in personalized oncology

XEPTAGEN SpA is engaged in the discovery and validation of novel molecular markers to improve the clinical management of cancer patients by creating innovative diagnostic tools that may allow a personalized treatment.

Products Highlight

Latest Product Literature

SCCA-IgM as a Potential Biomarker of Non-Alcoholic Fatty Liver Disease in Patients with Obesity, Prediabetes and Diabetes Undergoing Sleeve Gastrectomy. Obes Facts. 12:291–306. 2019.

MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma.. J Clin Med. 8(2). 2019.

Squamous cell carcinoma antigen 1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity.. Cancer Sci.. 110(5):1552-1563. 2019.

Actual evidences and future perspectives about the role of iXip® in the diagnosis of prostate cancer: a narrative review.. Minerva Urol Nefrol. . 2019.

Clinical significances and diagnostic utilities of both miR-215 and squamous cell carcinoma antigen-IgM versus alpha-fetoprotein in Egyptian patients with hepatitis C virus-induced hepatocellular carcinoma.. Clin Exp Gastroenterol.. 12:51-66. 2019.

Diagnostic accuracy of SCCA and SCCA-IgM for hepatocellular carcinoma: A meta-analysis. Liver Int.. 38:1820–1831. 2018.

Press Releases


Tweets by Xeptagen